Neuroendocrine Tumors (NETs)


Clinical Candidate: DOTA-TATE


PNT2003, also known as lutetium-177 Octreotate (177Lu-DOTATATE), is a somatostatin receptor (SSTR) targeted radioligand therapy in development for the treatment of patients with SSTR-positive neuroendocrine tumors.

SSTRs are seen as ideal targets for NET therapy. Somatostatin analogs (SSAs) have been developed with anti-secretory and anti-proliferative effects for NET therapy, and randomized clinical trials with somatostatin analogs have

demonstrated efficacy.

POINT has licensed both trial data as well as unique intellectual property from CanProbe, which enables the formulation of DOTA-TATE.

The formulation of DOTA-TATE licensed by POINT uses the medical isotope no-carrier added (n.c.a.) Lutetium-177. n.c.a Lutetium-177 is preferred by many clinics as it does not contain any long-lived radionuclides that can complicate administration and force the creation of costly specialized waste streams.

Lantheus and POINT Biopharma have announced a strategic collaboration and exclusive license agreements for the commercialization of PNT2003.

PNT2003’s trial is now fully enrolled and is expected to read out in 2022.